- PFROAD.com
- Posts
- Daily Money Pulse | 💰 Retirement Savings by Age; 🧓 Retire at 47?; 📜 Fair Will Check; 💼 Smart Ways to Use Inheritance
Daily Money Pulse | 💰 Retirement Savings by Age; 🧓 Retire at 47?; 📜 Fair Will Check; 💼 Smart Ways to Use Inheritance
In partnership with
📊 Market Snapshot
S&P 500 | 6022.24 | +0.27% |
|---|
Nasdaq | 19,615.88 | -0.50% |
|---|
Dow 30 | 42,865.77 | +0.00% |
|---|
📈 S&P 500 and Nasdaq rallied, moving closer to record highs amid renewed market optimism.
🌍 Positive momentum in U.S.-China trade talks boosted investor confidence and global sentiment.
💼 Tech and industrial stocks led the gains, reflecting hope for easing trade tensions.
Source : Click here
🟢Top Gainers
OKLO | $68.03 | +29.48% |
|---|
OKLO Inc. (OKLO) gained as investor optimism grew around its advanced nuclear reactor technology and recent developments in regulatory approval and commercial partnerships.
QUBT | $18.97 | +25.38% |
|---|
QUBT (Quantum Computing Inc.) gained as investors responded positively to advancements in its quantum software solutions and potential partnerships in AI and cybersecurity applications.
SMR | $41.60 | +20.41% |
|---|
SMR (NuScale Power Corporation) gained due to renewed investor interest in nuclear energy solutions amid rising demand for clean, scalable power and recent developments in small modular reactor projects.
Source : Click here.
1440: Your Weekly Business Cheat Sheet
Expand your business and finance knowledge with 1440. Get clear, conversational breakdowns of the key concepts in business and finance—no paywalls, no spin. Every Thursday, 1440 delivers deep dives, interactive charts, and rapid market rundowns trusted by 100k+ professionals.
🔴Top Losers
NEGG | $10.71 | -13.98% |
|---|
NEGG (Newegg Commerce Inc.) declined likely due to weak earnings performance, reduced e-commerce demand, or concerns about profitability amid rising competition in the online retail space.
LYEL | $09.41 | -12.87% |
|---|
LYEL (Lyell Immunopharma Inc.) declined due to investor concerns over ongoing clinical trial results, slow pipeline progress, or uncertainty around the commercial viability of its cell therapy programs.
SMMT | $19.58 | -11.32% |
|---|
SMMT (Summit Therapeutics Inc.) declined likely due to lack of recent clinical updates, investor caution around its drug pipeline, or profit-taking after prior gains.
Reply